Introduction
to activation of intracellular signalling pathways, whereas ligand binding characteristics were unchanged [8] : In specific cell types, the CCK2Ri4sv was constitutively active, leading to increased basal calcium mobilization and MAP kinase and Src kinase phosphorylation as compared with cells expressing wild-type CCK2 receptor [6, 9, 10] . Expression of constitutively active CCK2Ri4sv was associated with increased basal cell proliferation, and activation of the CCK2Ri4sv by ligand binding resulted in enhanced cell growth compared with the wild-type receptor [6, 8] . A second aberrant CCK2 receptor form that was identified in cancer, namely in a single case of human colorectal carcinoma, was a mutant with a single point mutation in the third intracellular loop [11] . This receptor form also led to increased cell proliferation, was, however, not associated with a tumorigenic potential as observed for experimental, not naturally occurring CCK2 receptor mutants [12] .
Splice variants with specific expression and functions in cancer such as the CCK2Ri4sv have been receiving increasing attention because of their possible role in tumour biology and potential use for diagnostic and/or therapeutic applications [13, 14] . One important step towards a better understanding of their functional or clinical relevance in cancer is the validation of their expression in human tumour tissues with respect to, for instance, their tumour selectivity, frequency and quantity [15] . As for the CCK2Ri4sv, only selected tumours have been investigated for this missplicing event so far. Although it has been found in colorectal, pancreatic and gastric adenocarcinomas as well as in Barrett's mucosa, a cancer precursor lesion [6, 7, [16] [17] [18] , it has not been quantified in all of these tissues. Moreover, tumours known for their particularly high CCK2 receptor levels have not been considered for their CCK2Ri4sv expression. In fact, the molecular mechanisms leading to intron 4 retention may not be restricted to the tumour types investigated so far, but could occur universally in cancers expressing the CCK2 receptor. [2] . [19] [20] [21] [22] [23] [24] [25] [26, 27] . 
Therefore, the aim of the present study was to quantitatively characterize the total CCK2 receptor, wild-type CCK2 receptor and CCK2Ri4sv expression at the transcriptional and protein level in a broader spectrum of different tumour types using end-point and real-time RT-PCR and in vitro receptor autoradiography. It was furthermore intended to assess the cancer selectivity of the CCK2Ri4sv by including normal tissues of tumour origin in the study. The primary focus was laid on gastrointestinal and lung tumours, as the CCK2 receptor is a marker for the major tumours of these organ systems

Materials and methods
Tissues
RNA extraction and reverse transcription
For reference sequences, see GenBank accession no. NM_176875 (human CCK2 receptor) and NG_007992 (human ␤-actin).
CCK2Ri4sv transcript expression was reported relative to total CCK2 receptor transcript expression as follows: [29, 30] .
Immunohistochemistry for the proliferation marker MIB-1 Table 2 ). The expression levels in the individual cases are shown in Fig. 3(A) . This figure also demonstrates how the relative splice variant amounts varied between the different tumour types. In SCLC, a significantly higher proportion of all CCK2 receptor transcripts corresponded to the splice variant than in GIST (P ϭ 0.0003) or insulinomas (P ϭ 0.0045).
Real-time PCR analysis furthermore revealed that the identification of the CCK2Ri4sv was associated with the amount of total CCK2 receptor mRNA. Tumours with splice variant expression showed significantly higher total receptor transcript levels than tumours without (P Ͻ 0.0001). This is shown in Fig. 3(B) Fig. 2(B) Fig. 3(B) .
Correlation of CCK 2 receptor binding site and transcript expression in tumour tissues
Receptor binding sites were not identified in over half of the tumours showing CCK2 receptor transcripts (Table 2). Real-time PCR analysis revealed that these autoradiographically negative tumours showed particularly low total CCK2 receptor transcript levels, whereas tumours with detectable receptor binding sites displayed significantly higher receptor mRNA amounts (P Ͻ 0.0001). This is demonstrated for the individual tumours in
Furthermore, it was found that in autoradiographically positive tumours the actual binding site density deviated considerably from that predicted from the transcript levels in a linear regression model in the majority of cases, as can be seen in Fig. 4(A) and (B).
Taking into account all autoradiographically positive and negative cases, the density levels of CCK2 receptor binding sites correlated statistically fairly well with total CCK2 receptor transcript levels (r 2 ϭ 0.6579, P ϭ 0.0002).
Discussion
The CCK2 receptor splice variant with intron 4 retention was previously described in a limited number of colorectal, pancreatic
and gastric adenocarcinomas [6, 7, 16, 17] . It was considered to be important in these particular tumours, because of its special functional characteristics, namely constitutive activity associated with increased proliferation [6] . Existing data indicate a high selectivity of the CCK2Ri4sv for tumours over non-neoplastic tissues, which is in fact much higher than that of the wild-type CCK2 receptor [6, 7, 16, 17, 31] . In the present series, the CCK2Ri4sv was not identified in a variety of normal gastrointestinal and lung tissues. It was in particular not detected in normal tissues of origin of tumours that frequently express it, such as gastric muscularis and lung. This extends previous findings of the absence of CCK2Ri4sv in normal colon and pancreas [6, 7, 16] . Of note, the CCK2Ri4sv may not absolutely be restricted to neoplasia, as it has been described in peripheral blood mononuclear cells of a minority of healthy individuals and in normal gastric mucosa [17, 31] [11] , in full agreement with our present findings. Furthermore, we could not detect the CCK2Ri4sv in gastric cancer or normal gastric mucosa where it had been described before [17] . Finally, the single cases of CCK2Ri4sv-expressing pancreatic adenocarcinomas reported in the literature suggested frequent CCK2 receptor missplicing in these tumours [7, 16] [17] . Furthermore, primers may underperform in amplification of low abundant transcripts when located in the vicinity of AG-rich stretches [32] which are present in intron 4 of the CCK2 receptor. On the other hand, it has to be considered that primers not able to distinguish between amplified cDNA and genomic DNA [6, 16] [34] .
The CCK2Ri4sv has been shown to stimulate cell proliferation in vitro [6, 7, 9, 35] [6, 7, 35] , whereas original tumour tissues express CCK2Ri4sv transcripts at very low levels and always together with high levels of wild-type CCK2 receptor and sometimes even CCK1 receptors [2] . In vivo, the CCK2Ri4sv may well dimerize with either of these receptors, similar to the wild-type CCK2 receptor [36] . Would [9, 15, 18, 37] (personal observations).
Given its high specificity for and high incidence in clinically important tumours like SCLC and GIST, the CCK2Ri4sv may represent an attractive target for potential clinical applications [13, 14] [38] [39] [40] . Conversely, targeting CCK2Ri4sv with a radioactive ligand, as suggested recently [41] , may be a less promising approach because accumulation of sufficient radioactivity within the tumour area for imaging or therapy may not be achieved because of the low tumoral CCK2Ri4sv expression levels. 
